Table 1.
Characteristic (N = 245) | Mean ± SD, number (%) |
---|---|
Age | 61.7 ± 12.1 |
Male sex (%) | 218 (89.0) |
Height (cm) | 168.2 ± 8.0 |
BMI (kg/m2) | 25.2 ± 4.0 |
Underlying disease | |
Hypertension (%) | 163 (66.5) |
Dyslipidemia (%) | 183 (74.7) |
Diabetes mellitus (%) | 81 (33.1) |
Atrial fibrillation (%) | 9 (3.7) |
Prior MI (%) | 26 (10.6) |
Prior PCI (%) | 33 (13.5) |
Prior CABG (%) | 4 (1.6) |
History of heart failure (%) | 6 (2.4) |
History of stroke (%) | 13 (5.3) |
Smoking history | |
Current smoker (%) | 82 (33.4) |
Past smoker (%) | 89 (36.3) |
Never smoked (%) | 74 (30.2) |
Medication | |
Calcium channel blockers (%) | 76 (31.0) |
Beta blockers (%) | 39 (16.0) |
ACE inhibitors (%) | 13 (5.3) |
ARBs (%) | 57 (23.3) |
Nitrates (%) | 14 (5.7) |
Nicorandil (%) | 10 (4.0) |
Statins (%) | 58 (23.7) |
Oral antidiabetic agents (%) | 46 (18.8) |
Insulin (%) | 7 (2.9) |
Aspirin (%) | 53 (21.6) |
Clopidogrel (%) | 16 (6.5) |
Prasugrel (%) | 6 (2.4) |
Cilostazol (%) | 6 (2.4) |
Ticlopidine (%) | 1 (0.4) |
SAPT (%) | 40 (16.3) |
DAPT (%) | 19 (7.8) |
Warfarin (%) | 1 (0.4) |
Rivaroxaban (%) | 2 (0.8) |
Apixaban (%) | 1 (0.4) |
Edoxaban (%) | 1 (0.4) |
Predonine (%) | 5 (2.0) |
Diagnosis | |
STEMI (%) | 149 (60.8) |
NSTEMI (%) | 48 (19.6) |
UA (%) | 48 (19.6) |
Emergent PCI (%) | 236 (96.3) |
Received PCI (%) | 243 (99.1) |
Length of hospital stay (d) | 9.8 ± 6.4 |
Length of hospital stay for STEMI (d) | 12.4 ± 6.1 |
Length of hospital stay for NSTEMI (d) | 7.4 ± 4.8 |
Length of hospital stay for UA (d) | 4.0 ± 3.0 |
ACE = angiotensin converting enzyme, ARBs = angiotensin II type I receptor blockers, BMI = body mass index, CABG = coronary artery bypass grafting, DAPT = dual antiplatelet therapy, MI = myocardial infarction, NSTEMI = non-ST elevation myocardial infarction, PCI = percutaneous coronary intervention, SAPT = single antiplatelet therapy, STEMI = ST elevation myocardial infarction, UA = unstable angina.